Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression in CML patie...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Mol Sci
Main Authors: Ohyashiki, Kazuma, Umezu, Tomohiro, Katagiri, Seiichiro, Kobayashi, Chiaki, Azuma, Kenko, Tauchi, Tetsuzo, Okabe, Seiichi, Fukuoka, Yutaka, Ohyashiki, Junko H.
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4849026/
https://ncbi.nlm.nih.gov/pubmed/27092489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17040570
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki